EuBiologics Co., Ltd
Bolstering the First-Line of Defense against Diseases

As advancing healthcare and innovation continue to save lives and eradicate scourges of the past, vaccination plays an instrumental role in this proven success, dramatically reducing the incidence of several infectious diseases. While a plethora of companies is committed to innovating vaccine development and supply, only a handful of them can be credited for the advancement of the latest technologies in this realm. EuBiologicsCo., Ltd is one of them. EuBiologics is redefining the development and supply of critical vaccines.

EuBiologics is a biopharmaceutical company that specializes in developing and supplying vaccines. “We contribute to promoting human health that lasts a lifetime through the development and production of high-quality, low-cost vaccines,” says Yeong Ok Baik, CEO at EuBiologics. As a contract research and manufacturing organization (CRMO), EuBiologics provides customized services for mammalian cell and microbial-derived biopharmaceuticals, from cell line development to GMP production. In fact, the services provided by EuBiologics are delivered in collaboration with leading global companies to help clients undertake their projects easily–thereby saving costs and time.

Initially established as an ideal strategic partner that provides proper solutions to clients on the development and manufacturing of products, the company is currently working on its CMO business through excellent GMP facilities. EuBiologics churns out non-clinical and clinical materials for vaccines and biopharmaceutical raw materials (DS) such as recombinant proteins, exosomes, and microbiome by using microbial fermenter (of capacity up to 1000L) and animal cell culture bioreactor (whose capacity ranges from 100L to 1000L). Besides CMO services, the company also expands its breadth of expertise on developing a bacterial vaccine pipeline that responds to the international vaccine for prevention, new epidemics, and antibiotic resistance. “For the development and manufacture of vaccines, we are constantly striving to secure world-class technology and quality to relieve the anxiety about humans’ infectious diseases such as COVID-19, and at the same time, we will do our best to make a healthier world,” Baik adds.

Touching upon the various challenges in this landscape, Baik mentions that CMO production is directly related to the product development schedule. This makes it imperative to remove any bottle-necks that might disrupt the delivery schedule, resulting in a loss of opportunity for customers to commercialize their products and expand business scope. In such an adverse scenario, the need to optimize the fermentation/purification process, method developments, scale-up techniques, and validation to produce non-clinical and clinical materials grows at large. However, these emerging companies that are looking forward to entering into the development stage after the successful completion of basic research on biopharmaceuticals lack sufficient facilities or experience to do so. “In such case, we provide detailed support and assist with GMP production of clinical samples to improve the development capabilities of SMEs,” he remarks.

As a biopharma company, EuBiologics goes the extra mile to guarantee the successful implementation of its customers’ projects. It thoroughly analyzes the manufacturing process and facilities, followed by preliminary conformity assessments to ensure that the production is adequate and efficient. In particular, the company offers two stellar products–rCRM197 and EcML, that proves beneficial for both EuBiologics and its clients. rCRM197 is a recombinant protein applied to EuVCT™ conjugate vaccine technology, whereas EcML is an adjuvant that is applied to EuIMT™ virus vaccine technology to promote successful vaccine development.

On Oct 1st, 2020, EuBiologics has established a Joint Venture (JV) with POP Biotechnologies (Pop Biotech, USA), so-called EUPOP Life Sciences in Buffalo, USA.

The ultimate goal for the JV is to develop premium vaccines and advance into the global market by combining immunoadjuvant technology of EuBiologics’ platform technology EuIMT^™ with SNAP (antigen delivery), which is Pop Biotech’s platform technology. Using such technologies, EuBiologics is planning to research and develop RSV (respiratory syncytial virus), VZV (herpes zoster virus), and Alzheimer’s vaccine as its primary goal. EuBiologics plans to become a full-fledged global vaccine company after setting the premium vaccine development pipeline, and in the future, they will continue cooperating with Pop Biotech, to possess anti-cancer drugs and vaccine delivery technology.

We contribute to promoting human health that lasts a lifetime through the development and production of high-quality, low-cost vaccines

At the core, EuBiologics is not just a two-dimensional outsourcing service infrastructure. The company pours in its in-depth knowledge to bolster quality standards and secure the competitiveness of the products. Predominantly, EuBiologics’ capability to provide customized service for R&D and biopharmaceutical products such as vaccines and protein therapeutics according to customers’ project stage is a unique addition that strengthens its plethora of services. EuBiologics’ expertise in improving the quality of the already released products is icing to the cake that imparts a touch of competitiveness in the market.

At heart, EuBiologics’ CRMO business is a combined outcome that demonstrates both safety and efficacy of the product and the excellent quality management system and manufacturing process. As a Korean bio-venture firm, EuBiologics takes pride in its broad spectrum of services that make it more responsible for helping its clients accomplish their vaccine implementations. Further elaborating on this aspect, Baik presents a client success story wherein EuBiologics worked with the client to streamline the production of clinical trial phase 3 bulk using other biopharmaceutical company’s animal cellbased vaccine. The manufacturing of the vaccine had to be carried out in combination with process validation (PV) and cleaning validation (CV). This was deemed complicated and difficult for the client. The company conducted technical meetings and constant communication with customers, trying to enhance product quality. EuBiologics was able to accelerate the process and complete the project within the stipulated time while maintaining the highest standards of production.

Such success stories stand testament to the value that EuBiologics has been delivering to its clients, even during the current worldwide outbreak of COVID-19. In its attempt to make the world a healthier place and relieve mankind from highly contagious diseases, EuBiologics is driving the development of quality vaccines. Especially after the high demand for cholera vaccines at the UNICEF, the company plans to increase its sales capabilities and meet the demand. EuBiologics has recently established a new production space in the 2nd factory (V plant), Dongchuncheon Industrial Complex, to increase vaccine production. In fact, the company expects to produce Euvichol Plus® up to 50 million doses per year in the newly opened plant. To rapidly develop preventive vaccines for infectious diseases and provide worldwide relief, EuBiologics plans to strengthen its network with domestic and foreign companies to expand its CRMO business. “As we are also expecting continued growth of profits from clinical material production of one biopharmaceutical company (Europe) and other CMO-related business, we expect high growth to be continued in the next two years,” concludes Baik.